ERBB2 and breast carcinoma: However, the development of targeted anti-HER2 therapies based principally on humanized antibodies (such as trastuzumab, trastuzumab emtansine -T-DM1 or pertuzumab) and tyrosine kinase inhibitors (such as lapatinib) has dramatically improved the outcome of women with early and advanced stage HER2-positive breast cancer [4–11].